The history of antibiotics represents one of the most transformative arcs in the annals of medicine, effectively demarcating the transition of the human species from a state of vulnerability to infectious pathogens to one of clinical dominance. Prior to the mid-20th century, infectious diseases were the primary drivers of global morbidity and mortality, with life expectancy in even the most industrialized nations restricted to approximately 47 years.¹ The subsequent development of antimicrobial agents not only extended the average human lifespan by more than two decades but also provided the necessary safety net for the advancement of complex medical interventions such as oncology, organ transplantation, and advanced surgery.¹ This analysis explores the trajectory of antibiotic development, from its empirical roots in antiquity to the contemporary challenges of antimicrobial resistance and the innovative policy models designed to revitalize a stagnating pipeline.

Antiquity and the Empirical Foundations of Mycotherapy

While the formal scientific categorization of antibiotics is a product of the 20th century, the intentional application of substances with antimicrobial properties is deeply rooted in ancient history. Research into Nubian skeletal remains from northern Sudan, dating to 350–550 CE, reveals that these ancient societies systematically consumed high levels of tetracycline.³ The chemical signature found in their bones indicates that the antibiotic was not consumed accidentally but was likely a byproduct of a specialized fermentation process used in brewing beer from grain.³ The presence of Streptomyces, a bacterium that naturally produces tetracycline, in the fermentation environment suggests that these populations had identified and cultivated specific microbial processes to promote health and prevent disease.³

The use of molds—filamentous fungi—as curative agents for topical infections is a recurring motif across diverse global cultures. In ancient Egypt, the Edwin Smith Papyrus and the Ebers Papyrus, dating back to 1550 BCE, document sophisticated medical practices that included the application of moldy bread to infected wounds.⁴ Imhotep, an architect and physician to Pharaoh Djoser in the 26th century BCE, is credited with using moldy bread to treat facial infections, a practice that likely exploited the antimicrobial metabolites produced by specific fungal species.⁵ Similarly, ancient Chinese records from 3000 BCE mention the use of moldy soybean curd (tofu) to treat skin infections, while Greek and Roman physicians, including Hippocrates and Galen, utilized moldy wine-soaked dressings to manage post-traumatic sepsis.⁷

Beyond fungi, other natural products were utilized for their inherent antibacterial properties. Honey has been used extensively in Egypt, China, and Greece as a potent wound healer and antibiotic; modern microbiological analysis confirms that its high osmolarity and enzymatic production of hydrogen peroxide make it a formidable barrier to bacterial growth, to which resistance rarely develops.⁴ Turmeric, utilized for nearly 4000 years in South Asia, and the use of poppy seeds for pain relief (containing morphine and codeine precursors) further illustrate the sophisticated, albeit empirical, pharmacopeia of the ancient world.⁴ These practices demonstrate that human societies recognized the antagonistic relationship between certain natural substances and disease-causing agents long before the formalization of the germ theory of disease.

The Dawn of Modern Chemotherapy: Paul Ehrlich and the Magic Bullet

The scientific revolution in antimicrobial therapy began in Germany during the late 19th and early 20th centuries, driven by the pioneering work of Paul Ehrlich. Ehrlich hypothesized that if specific dyes could selectively stain certain bacterial cells while leaving human tissue untouched, then chemical compounds could be engineered to selectively bind to and destroy pathogens.⁹ This concept, which he termed the “magic bullet” (therapia sterilisans magna), laid the foundation for modern chemotherapy—a term Ehrlich himself coined to describe the planned chemical synthesis of therapeutic agents.¹¹

Ehrlich’s primary focus was the spirochete Treponema pallidum, the causative agent of syphilis, which at the time was a major public health crisis treated with highly toxic and largely ineffective inorganic mercury compounds.¹¹ In 1907, in collaboration with the organic chemist Alfred Bertheim and the Japanese bacteriologist Sahachiro Hata, Ehrlich’s lab began a systematic screening of hundreds of newly synthesized organic arsenical compounds.¹³ Hata, who had worked on bubonic plague research, developed an effective rabbit model for syphilis that allowed for precise in vivo testing of these compounds.¹⁴

Success was achieved with compound 606, which Ehrlich and Hata announced in 1910 under the trade name Salvarsan.¹³ Salvarsan was the first modern antimicrobial agent, though its chemistry and administration were fraught with difficulty. For nearly a century, Salvarsan was believed to possess an arsenic-arsenic double bond (), but mass spectrometric analysis in 2005 revealed it to be a mixture of cyclic species, primarily and , where R is the 3-amino-4-hydroxyphenyl moiety.⁹ These cyclic species slowly release an oxidized monomer, , which acts as the active antisyphilitic agent.¹³

The introduction of Salvarsan marked a critical turning point in human history, although its clinical use was complex. The drug was supplied as a yellow, crystalline powder that was highly unstable in air and required meticulous preparation, including neutralization with sodium hydroxide before injection into the patient.⁹ Despite side effects such as nausea, liver damage, and “burning up veins,” Salvarsan and its more soluble derivative, Neosalvarsan (introduced in 1912), remained the gold standard for syphilis treatment until the mid-1940s.¹³

The Sulfonamide Era: The First Synthetic Broad-Spectrum Antibacterials

While Salvarsan addressed specific spirochetal and parasitic infections, the search for a broad-spectrum antibacterial agent effective against common pathogens like Streptococcus and Staphylococcus continued. This search culminated in the 1930s at the Bayer Laboratories of the IG Farben conglomerate in Germany, where a research team led by Gerhard Domagk investigated the therapeutic potential of synthetic azo dyes.¹⁰

In 1932, Domagk discovered that a red dye called Prontosil rubrum was effective in treating lethal streptococcal infections in mice.¹⁰ The clinical significance of this finding was highlighted when Domagk used the drug to save his daughter, Hildegarde, from a severe streptococcal infection following an accidental needle prick.¹⁰ Subsequent research at the Pasteur Institute in Paris clarified the mechanism of action: Prontosil was a prodrug that was broken down within the human body to release sulfanilamide, the actual active antimicrobial agent.¹⁰ Because sulfanilamide had been synthesized for decades and was no longer under patent, it could be produced inexpensively by various manufacturers, leading to a proliferation of “sulfa drugs”.¹⁰

Sulfonamides revolutionized the treatment of pneumonia, meningitis, and maternal sepsis. In the United States alone, the introduction of sulfa drugs resulted in a 36% decline in maternal mortality rates and a 24% decline in deaths from influenza and pneumonia.²⁰ However, the rapid emergence of resistance, which was reported almost immediately following the drug’s widespread introduction, signaled the beginning of a persistent evolutionary “neck-on-neck race” between medical science and bacterial adaptation.²¹

The Penicillin Revolution: From Accidental Discovery to Industrial Triumph

The most iconic moment in the history of antibiotics occurred in September 1928 at St. Mary’s Hospital in London. Alexander Fleming, a bacteriologist who had served in the British Medical Corps during World War I, returned from a vacation to find a contaminated petri dish where a blue-green mold, identified as Penicillium notatum, had inhibited the growth of surrounding Staphylococcus aureus colonies.¹² Fleming extracted the “mold juice” and named the active agent penicillin, noting its effectiveness against Gram-positive pathogens like those causing scarlet fever, diphtheria, and pneumonia.¹²

Fleming published his findings in 1929, but for the next decade, penicillin remained a laboratory curiosity.¹² Fleming and his colleagues, including the biochemist Harold Raistrick, struggled to isolate the unstable molecule in quantities sufficient for clinical use.¹² interest was reignited in 1937 at Oxford University, where Howard Florey and Ernst Chain assembled a multidisciplinary team to systematically investigate antibacterial substances produced by microorganisms.²⁴

The Oxford team, which included the innovative engineer Norman Heatley, developed a method for the extraction and purification of penicillin using a complex process of back-extraction and freeze-drying.²⁴ The production process was initially so inefficient that the team resorted to using unconventional vessels like bedpans, milk churns, and bathtubs to grow the mold broth.²⁴ On May 25, 1940, the team conducted a definitive experiment on eight mice infected with lethal doses of Streptococcus: the four mice treated with penicillin survived, while the untreated controls died.²⁵

Scaling Production: The Peoria Breakthrough and WWII

With Britain’s industrial capacity diverted to the war effort, Florey and Heatley traveled to the United States in June 1941 to seek assistance in mass-producing penicillin.²⁴ In Peoria, Illinois, at the USDA’s Northern Regional Research Laboratory, the project underwent a radical transformation. Researchers discovered that corn-steep liquor, a nitrogen-rich byproduct of the corn starch industry, exponentially increased the yield of penicillin when added to the fermentation broth.²⁴ Furthermore, the discovery of a highly productive strain of Penicillium chrysogenum on a rotting cantaloupe in a Peoria market provided a biological engine far more powerful than Fleming’s original strain.²⁴

The final hurdle was the transition from surface cultivation in shallow trays to deep-tank fermentation. This technology was pioneered by the Pfizer Corporation, which adapted its experience with the aerobic fermentation of citric and gluconic acids to create 10,000-gallon stirred tanks that could maintain sterility and adequate aeration.²⁶ By early 1944, American production had scaled to the point that penicillin was available for all military casualties on D-Day, and by 1945, it was widely accessible to the civilian public.²⁵

The Golden Age of Antibiotic Discovery (1940–1962)

The success of penicillin triggered an era of intensive “bioprospecting” known as the Golden Age of Antibiotics. This period was largely defined by the “Waksman platform,” named after Selman Waksman, a soil microbiologist at Rutgers University.¹⁸ Waksman and his team systematically screened soil-dwelling Actinobacteria, particularly those in the genus Streptomyces, for the production of antagonistic metabolites.¹⁶

In 1943, Waksman and his PhD student Albert Schatz discovered streptomycin, the first antibiotic effective against the “White Plague”—tuberculosis (TB).² Streptomycin’s discovery was a pivotal moment, as it addressed the massive gap left by penicillin, which was ineffective against the Gram-negative mycobacteria causing TB.⁸ Waksman, who was awarded the Nobel Prize in 1952, also coined the term “antibiotic” to describe substances produced by microorganisms that inhibit the growth of other microbes.³

Between 1940 and 1962, more than 20 new classes of antibiotics were introduced to the market.³³ These included broad-spectrum agents that fundamentally changed the management of infectious disease:

1. Chloramphenicol (1947): The first antibiotic to be synthesized chemically on a commercial scale, effective against a wide range of Gram-positive and Gram-negative bacteria, as well as Rickettsial organisms.¹⁹
2. Tetracyclines (1948): Discovered by Benjamin Duggar at Lederle Laboratories, these broad-spectrum agents became a mainstay of therapy due to their oral bioavailability and effectiveness against diverse pathogens.¹⁹
3. Cephalosporins (1945/1953): Originally isolated from Cephalosporium acremonium found in a Sardinian sewage outfall, these drugs offered a lower toxicity profile and a broader spectrum than penicillin.⁷
4. Macrolides (1952): Erythromycin was the first of this class, providing an alternative for patients allergic to penicillin and effective against respiratory pathogens.¹⁹
5. Vancomycin (1955): A glycopeptide often referred to as a “drug of last resort,” it remained effective against resistant staphylococci for decades after its discovery.¹⁹

By the end of the 1960s, the medical community’s optimism was at an all-time high, with some even suggesting that the war against infectious diseases had been won. However, this period of rapid discovery also facilitated the widespread misuse and overuse of antibiotics in both human medicine and agriculture, setting the stage for the modern antimicrobial resistance crisis.²¹

Industrial Evolution: Fermentation and the Biotech Legacy

The mass production of penicillin was not just a medical breakthrough but an engineering one that established the foundations of modern biotechnology. Prior to World War II, industrial fermentation was used primarily for the production of organic acids like citric and gluconic acids.²⁶ Pfizer, then a small chemical firm in Brooklyn, had pioneered the use of shallow trays for citric acid fermentation after the supply of Italian lemons was cut off during World War I.²⁶

The critical innovation for penicillin was the development of submerged aerobic fermentation in large, stirred-tank fermenters.²⁹ Because the Penicillium mold is aerobic, it requires a constant supply of sterile air. Engineers at Pfizer and other firms perfected the design of impellers and spargers to distribute air through thousands of gallons of viscous broth without contaminating the culture or disrupting the delicate fungal cells.²⁶ This technology, often referred to as a “rarely acknowledged pillar of the modern age,” was subsequently used to manufacture every major class of natural product antibiotics discovered during the Golden Age.²⁹

Furthermore, the scale of the penicillin project—a massive collaboration between the British and American governments, academia, and over 20 pharmaceutical companies—transformed the industry.²⁸ It moved pharmaceutical companies away from being simple purveyors of chemicals and dyes toward becoming research-intensive organizations focused on biological manufacturing.¹² This industrial infrastructure later paved the way for the production of recombinant proteins like insulin and growth hormones in the 1970s and 1980s.³⁸

The Parallel History: Phage Therapy and the Soviet Experience

While the Western world focused almost exclusively on chemical antibiotics, a different therapeutic paradigm flourished in the Soviet Union and Eastern Europe. Bacteriophage therapy—the use of viruses that selectively infect and lyse bacteria—was discovered independently by Frederick Twort in 1915 and Félix d’Hérelle in 1917.³⁹ d’Hérelle, a Canadian autodidact, observed “clear circles” on bacterial cultures, which he correctly identified as the result of viral predation.⁴²

d’Hérelle’s work led to the establishment of the George Eliava Institute of Bacteriophage, Microbiology and Virology in Tbilisi, Georgia, in 1923.³⁹ Phage therapy was used extensively in the Soviet Union to treat a wide range of infections, including dysentery, typhoid fever, and surgical site infections.³⁹ During World War II, Soviet surgeons like Tsulukidze and Beridze utilized phages in urology and dermatology, publishing their results in Russian-language journals that were largely inaccessible to Western scientists.³⁹

Phage therapy faced skepticism in the West due to the lack of double-blind, placebo-controlled trials, the high specificity of phages (which required individualized “phage matching”), and the overwhelming success of broad-spectrum antibiotics.³⁹ However, as antibiotic resistance has rendered traditional drugs ineffective, there is a significant modern resurgence in phage research. Innovations such as “phage cocktails,” engineered phages using CRISPR-Cas technology, and the use of phage-derived enzymes (lysins) are now being explored as critical tools in the post-antibiotic era.³⁹

The Public Health Impact: Statistics of a Transformed World

The introduction of antibiotics resulted in one of the most rapid and dramatic shifts in human health outcomes in history. Before antibiotics, minor injuries—paper cuts, scratches, or childbirth—could be fatal through the onset of sepsis.²⁰ The “miracle” of these drugs is best captured by the reduction in mortality rates across several critical domains.

Maternal and Neonatal Mortality

In the early 20th century, the nationally reported maternal mortality ratio in the United States was 619 deaths per 100,000 live births; in England and Wales, it was 411.⁴⁴ Puerperal fever, often caused by Streptococcus pyogenes, was the leading cause of these deaths. Following the introduction of sulfonamides in 1936 and penicillin in the 1940s, these ratios plummeted.⁴⁴ By 1960, the U.S. maternal mortality ratio had fallen to 37 per 100,000 live births—a nearly 17-fold reduction.⁴⁴

Infant mortality followed a similar trajectory. In 1900, infant mortality rates ranged from 100 to 200 per 1,000 births, often fluctuating with the seasons and epidemic cycles.⁴⁶ While improvements in hygiene and sanitation drove the initial decline, the introduction of antibiotics and vaccinations in the mid-20th century accelerated the trend, bringing the U.S. rate to 7 per 1,000 by 1997.⁴⁶ Today, more than 200,000 newborns die each year from infections that are resistant to available drugs, emphasizing that these gains are fragile.⁴⁷

Surgical and Post-Operative Mortality

The feasibility of modern surgery is entirely dependent on the prevention of surgical site infections (SSIs). In the pre-antibiotic era, routine surgeries carried high risks, with postoperative mortality rates of 60%–80% being common for more invasive procedures.⁴⁸ Most of these deaths were due to “hospital gangrene” or streptococcal sepsis.⁴⁸

A comprehensive study of Pennsylvania Medicare patients undergoing general surgery demonstrated that those who received preoperative antibiotics within two hours of incision had a mortality risk less than half of those who did not receive such treatment (Odds Ratio = 0.44).⁵⁰ Furthermore, advanced medical procedures such as solid organ transplants and bone marrow transplants would be impossible without antibiotics; transplant recipients are at extreme risk for infections due to necessary immunosuppression.¹ Recent data indicates that antibiotic treatment prior to liver transplants significantly reduces inflammatory damage and organ rejection, improving both graft and patient survival.⁵³

The Discovery Void: Economic and Regulatory Stagnation

Since the late 1960s, the “Golden Age” of discovery has given way to a “Discovery Void.” No new classes of antibiotics have been discovered since 1987, and most drugs reaching the market are merely analogues of existing classes.¹ This stagnation is driven by a profound “market failure” in the pharmaceutical industry.

Economic Barriers

The traditional pharmaceutical business model, which relies on high-volume sales to recoup research and development (R&D) costs, is fundamentally incompatible with antibiotic sustainability. Unlike drugs for chronic conditions such as hypertension or diabetes—which patients take daily for decades—antibiotics are used for short durations (typically 7–14 days) and are meant to be curative.³¹ Furthermore, to preserve the effectiveness of new, innovative antibiotics, clinicians often keep them “on the shelf” as a last resort, leading to low sales volumes.⁵⁵

As a result, 18 of the 20 largest pharmaceutical companies have abandoned antibiotic R&D since the 1990s.³² The field is now dominated by small and medium enterprises (SMEs), many of which have filed for bankruptcy despite having successful drugs approved because they cannot generate enough revenue to sustain their operations.⁵⁵

Regulatory Challenges

Proving the efficacy of a new antibiotic is technically challenging. Regulators like the FDA generally require clinical trials that demonstrate “superiority” or “non-inferiority” against existing drugs.⁵⁵ However, because multidrug-resistant infections are still relatively rare compared to susceptible ones, it is difficult for manufacturers to recruit enough patients for large-scale trials.⁵⁵ The cost of bringing a new antibiotic to market is now estimated to be between hundreds of millions and over one billion US dollars, while the global sales of some branded antibiotics are less than $1 billion annually.⁵⁵

Policy Innovation: Delinkage and the PASTEUR Act

To address the market failure, policy experts have proposed “delinkage” models, which separate a company’s revenue from the volume of drug sales.³² These models aim to provide a predictable return on investment while encouraging appropriate stewardship.

The most prominent example in the United States is the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act.⁵⁶ Under this bipartisan legislation, the federal government would enter into “subscription-style” contracts with pharmaceutical companies that develop critically needed new antibiotics.⁵⁶ Companies would receive fixed annual payments (ranging from $75 million to $300 million) regardless of how often the drug is used, in exchange for ensuring global access and complying with stewardship programs.³²

These models represent a shift toward viewing antibiotics as “social infrastructure” or “fire extinguishers”—tools that must be maintained and ready for use even if they are rarely deployed.⁵⁵

The Modern Frontier: AI and Novel Antibiotic Scaffolds

As traditional soil screening (the Waksman platform) has reached a point of diminishing returns, researchers are turning to cutting-edge technologies to find the next generation of antibiotics.

Artificial Intelligence and SyntheMol

Artificial intelligence is being deployed to explore the vast “chemical space” of possible drug-like molecules, estimated to be as large as .⁶³ Researchers at Stanford recently developed an AI model called SyntheMol, which generated chemical recipes for six novel drugs designed to kill Acinetobacter baumannii, a leading cause of hospital-acquired infections.⁶³ Unlike previous AI models that only identified existing compounds, SyntheMol provides blueprints for synthesizing entirely new molecules, bridging the gap between computational prediction and laboratory validation.⁶³

Natural Product Breakthroughs: Teixobactin and Clovibactin

Innovations in cultivation technology, such as the iChip, have allowed scientists to grow “unculturable” bacteria in their natural soil environments.⁶⁴ This led to the discovery of teixobactin, a powerful antibiotic that kills Gram-positive bacteria by binding to lipid II and lipid III—highly conserved precursors of the bacterial cell wall.⁶⁴ Because these targets are immutable and do not easily change, teixobactin is considered “resistance-proof” in preclinical models.⁶⁴

In 2023, the discovery of clovibactin was reported; isolated from unculturable soil bacteria, it uniquely binds to cell wall precursors to provide efficient killing without detectable resistance development.⁶⁴ Furthermore, researchers at the University of Liverpool announced “NovItex” in 2025, a new class of synthetic antibiotics inspired by teixobactin that is 30 times more efficient to produce and highly effective against MRSA and VRE.⁶⁵

Exploiting the Extremes: Ice Caves and Deep Sea Vents

Extreme environments are also yielding novel antimicrobial strategies. Bacteria isolated from a 13,000-year-old ice core in the Scarisoara Ice Cave, Romania, have shown antimicrobial activity against 22 human pathogens, offering a potential reservoir for new bioactive molecules.⁶⁷ Similarly, the discovery of a functional antibacterial lysozyme in Archaea inhabiting deep-sea hydrothermal vents suggests that these ancient organisms possess defensive genes that have never been exploited in human medicine.⁶⁸

Conclusion: Securing the Future of the Antibiotic Era

The history of antibiotics has come full circle. We have moved from the empirical use of moldy bread to the systematic engineering of “magic bullets,” through a “Golden Age” of soil-mining, and into a contemporary “Discovery Void” characterized by economic stagnation and evolutionary pressure.²³ The achievements of the 20th century—the dramatic decline in maternal and surgical mortality and the doubling of the human lifespan—are now under threat by the global rise of antimicrobial resistance.¹

Securing the future requires a holistic “One Health” approach that integrates innovative drug discovery via AI and extreme environments, legislative reform through subscription models like the PASTEUR Act, and a renewed focus on bacteriophage therapy as a viable alternative.⁴⁰ The history of antibiotics is not a finished chapter but an ongoing struggle that requires constant adaptation to match the extraordinary genetic capacity of the microbial world.²¹ Only through a sustained, global commitment to both innovation and stewardship can the medical community ensure that the “miracle drugs” of the 20th century continue to protect human health in the 21st.

Works cited

1. THE TREASURE CALLED ANTIBIOTICS – PMC – NIH,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC5354621/
2. Antibiotics: past, present and future – PubMed,  , https://pubmed.ncbi.nlm.nih.gov/31733401/
3. Antibiotic – Wikipedia,  , https://en.wikipedia.org/wiki/Antibiotic
4. TRADITIONAL MEDICINE: Using our Past to Advance Our Future | Distilled Periodical,  , https://yaledistilled.sites.yale.edu/browse-issues/2019-issue/traditional-medicine-using-our-past-advance-our-future
5. Mycelium of fungi isolated from mouldy foods inhibits Staphylococcus aureus including MRSA – A rationale for the re-introduction of mycotherapy? – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC4537866/
6. Egyptians Anticipated Antibiotics By Millennia By Using Moldy Bread – World Atlas,  , https://www.worldatlas.com/ancient-world/egyptians-anticipated-antibiotics-by-millinia-by-using-moldy-bread.html
7. Moulds, Arsenic, Soil and Sewage – a brief history of antimicrobials – AMR Vet Collective,  , https://www.amrvetcollective.com/home/latest-news/moulds-arsenic-soil-and-sewage-a-brief-history-of-antimicrobials/
8. When Mold Became Medicine: The History of Antibiotics – Nerdish,  , https://nerdish.io/blog/when-mold-became-medicine-the-history-of-antibiotics/
9. As published in Chemistry in New Zealand 69 (2005) 24 SALVARSAN – THE FIRST CHEMOTHERAPEUTIC COMPOUND – Research Commons,  , https://researchcommons.waikato.ac.nz/server/api/core/bitstreams/d06a05a6-16f5-42a2-ba6e-295db95d0ab2/content
10. Gerhard Domagk | History | Research Starters – EBSCO,  , https://www.ebsco.com/research-starters/history/gerhard-domagk
11. Ehrlich Introduces Salvarsan as a Cure for Syphilis | History | Research Starters – EBSCO,  , https://www.ebsco.com/research-starters/history/ehrlich-introduces-salvarsan-cure-syphilis
12. The Discovery of Penicillin—New Insights After More Than 75 Years …,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC5403050/
13. Arsphenamine – Wikipedia,  , https://en.wikipedia.org/wiki/Arsphenamine
14. Syphilis and Salvarsan – PMC – NIH,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC6478456/
15. Early Solution – Science History Institute,  , https://www.sciencehistory.org/stories/magazine/early-solution/
16. Microbiology Study Guide: Antimicrobial Agents & Antibiotics | Notes – Pearson,  , https://www.pearson.com/channels/microbiology/study-guides/the-history-of-antimicrobial-agents
17. Antibiotics – Didusch Museum,  , https://urologichistory.museum/histories/urologic-treatment/antibiotics
18. History of Chemotherapy and Antimicrobial Discovery | Microbiology – Lumen Learning,  , https://courses.lumenlearning.com/suny-microbiology/chapter/history-of-chemotherapy-and-antimicrobial-discovery/
19. Timeline of antibiotics – Wikipedia,  , https://en.wikipedia.org/wiki/Timeline_of_antibiotics
20. Antibiotics and Antibiotic Resistance – Our World in Data,  , https://ourworldindata.org/antibiotics
21. Origins and Evolution of Antibiotic Resistance – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC2937522/
22. Antibiotics and antimicrobial resistance – a timeline – Science Learning Hub,  , https://www.sciencelearn.org.nz/interactive_timeline/15-antibiotics-and-antimicrobial-resistance-a-timeline
23. History of Antibiotics Research – PubMed,  , https://pubmed.ncbi.nlm.nih.gov/27738915/
24. How was penicillin developed? – Science Museum,  , https://www.sciencemuseum.org.uk/objects-and-stories/how-was-penicillin-developed
25. Fact Sheet: The Challenge of Mass Production – The National WWII Museum,  , https://www.nationalww2museum.org/sites/default/files/2017-07/penicillin-fact-sheet.pdf
26. Penicillin Production through Deep-tank Fermentation – National Historic Chemical Landmark,  , https://www.acs.org/education/whatischemistry/landmarks/penicillin.html
27. Penicillin: the Oxford story,  , https://www.ox.ac.uk/news/science-blog/penicillin-oxford-story
28. From Small Wonder to Big Salvation: – Mississippi Department of Archives & History,  , https://www.mdah.ms.gov/sites/default/files/2024-06/Harrison-Shao.pdf
29. Innovators, deep fermentation and antibiotics: promoting applied science before and after the Second World War,  , https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-95362011000200004
30. Rethinking Antibiotic Research and Development: World War II and the Penicillin Collaborative – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC3673487/
31. What was the Golden Age of Antibiotics, and how can we spark a new one?,  , https://ourworldindata.org/golden-age-antibiotics
32. Current economic and regulatory challenges in developing …,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC12159177/
33. Novel classes of antibiotics or more of the same? – PMC – NIH,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC3085877/
34. History Repeating? Avoiding a Return to the Pre-Antibiotic Age – Harvard DASH,  , https://dash.harvard.edu/bitstreams/7312037c-ab46-6bd4-e053-0100007fdf3b/download
35. Where have All the Antibiotics Gone? – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC2095086/
36. Derivation of a Precise and Consistent Timeline for Antibiotic …,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC9495031/
37. Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC10056106/
38. A Brief History of Microbial Biomanufacturing: Where We’ve Been and Where We Are Going,  , https://cytovance.com/news-articles/a-brief-history-of-microbial-biomanufacturing/
39. Phage Therapy-History from Twort and d’Herelle Through Soviet …,  , https://www.researchgate.net/publication/228100500_Phage_Therapy-History_from_Twort_and_d’Herelle_Through_Soviet_Experience_to_Current_Approaches
40. The Evolution of Phage Therapy: A Comprehensive Review of …,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC11519598/
41. The strange history of phage therapy – PMC – NIH,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC3442826/
42. Félix d’Hérelle, discoverer of bacteriophages | – Institut Pasteur,  , https://www.pasteur.fr/en/institut-pasteur/history/felix-herelle-discoverer-bacteriophages
43. Phage therapy–history from Twort and d’Herelle through Soviet experience to current approaches – PubMed,  , https://pubmed.ncbi.nlm.nih.gov/22748807/
44. Maternal Mortality in the United States: A Primer | Commonwealth Fund,  , https://www.commonwealthfund.org/sites/default/files/2020-12/Declercq_maternal_mortality_primer_db.pdf
45. Maternal Mortality – Our World in Data,  , https://ourworldindata.org/maternal-mortality
46. The First Measured Century: Timeline: Data – Mortality – PBS,  , https://www.pbs.org/fmc/timeline/dmortality.htm
47. Antibiotics, childbirth, and maternal and infant mortality – The World Economic Forum,  , https://www.weforum.org/stories/2016/08/antibiotics-childbirth-and-maternal-and-infant-mortality/
48. Infection control through the ages – Colorado Hospital Association,  , https://cha.com/wp-content/uploads/2017/11/AJIC-2012-Infection-Control-Through-the-Ages.pdf
49. Antibiotic Prophylaxis in Surgery: Current Insights and Future Directions for Surgical Site Infection Prevention – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC10680052/
50. Preoperative Antibiotics and Mortality in the Elderly – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC1357711/
51. Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC7437398/
52. Prognostic study to detect ailments, including cancer, during solid organ transplantation to prevent postoperative complications using perioperative antibiotics therapy,  , https://www.oncologyradiotherapy.com/articles/prognostic-study-to-detect-ailments-including-cancer-during-solid-organ-transplantation-to-prevent-postoperative-complic.pdf
53. Antibiotics before liver transplants lead to better results – UCLA Health,  , https://www.uclahealth.org/news/release/antibiotics-before-liver-transplants-lead-to-better-results
54. The antibiotic discovery void – HealthyWomen,  , https://www.healthywomen.org/your-care/science-and-technology/antibiotic-resistance-crisis-point/the-antibiotic-discovery-void
55. Antibiotic development — economic, regulatory and … – JPIAMR,  , https://jpiamr.eu/app/uploads/2021/08/Antibiotic-development-economic-regulatory-and-societal-challenges.pdf
56. Updated PASTEUR Act reintroduced in Congress to boost antibiotic development – CIDRAP,  , https://www.cidrap.umn.edu/antimicrobial-stewardship/updated-pasteur-act-reintroduced-congress-boost-antibiotic-development
57. The PASTEUR Act – Buddy Carter,  , https://buddycarter.house.gov/UploadedFiles/PASTEUR_Act_2026_-One_Pager.pdf
58. Putting the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act Under the Microscope – NCBI,  , https://www.ncbi.nlm.nih.gov/books/NBK620102/
59. Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House – AMR.Solutions,  , https://amr.solutions/2020/12/09/global-survey-of-novel-antibiotic-reimbursement-models-pasteur-act-introduced-to-us-house/
60. Few antibiotics under development – How did we end up here?,  , https://www.reactgroup.org/toolbox/understand/how-did-we-end-up-here/few-antibiotics-under-development/
61. Availability to particularly important antibiotics – a Swedish pilot study – Folkhälsomyndigheten,  , https://www.folkhalsomyndigheten.se/contentassets/700919bb88944affbfe814c1b23e53ed/availability-to-antibiotics-of-particular-importance.pdf
62. Reimbursement models to tackle market failures for antimicrobials – AIR Unimi,  , https://air.unimi.it/retrieve/fec764ad-ce4b-42cc-ba54-fb95b518a294/1-s2.0-S0168851020302980-main.pdf
63. Generative AI develops potential new drugs for antibiotic-resistant bacteria,  , https://med.stanford.edu/news/all-news/2024/03/ai-drug-development.html
64. Press Releases – NovoBiotic Pharmaceuticals,  , https://www.novobiotic.com/news
65. New antibiotic boosts our fight against multidrug-resistant bacteria – BioTechniques,  , https://www.biotechniques.com/drug-discovery-development/new-antibiotic-boosts-our-fight-against-multidrug-resistant-bacteria/
66. Liverpool scientists lead discovery of powerful new antibiotic class to tackle deadly superbugs – News,  , https://news.liverpool.ac.uk/2025/09/18/liverpool-scientists-lead-discovery-of-powerful-new-antibiotic-class-to-tackle-deadly-superbugs/
67. Cave ice microbiome – reservoir for new biomolecules in medicine and biotechnologies – Digital Commons @ USF,  , https://digitalcommons.usf.edu/cgi/viewcontent.cgi?article=1026&context=egri_frontiers
68. Life’s extremists may be an untapped source of antibacterial drugs – Vanderbilt University,  , https://news.vanderbilt.edu/2014/11/21/lifes-extremists-may-be-an-untapped-source-of-antibacterial-drugs/
69. From Cure to Crisis: Understanding the Evolution of Antibiotic-Resistant Bacteria in Human Microbiota – MDPI,  , https://www.mdpi.com/2218-273X/15/1/93